This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.83% per year. These returns cover a period from January 1, 1988 through January 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
marijuana: Archive
Cannabis Operator Curaleaf Plunges 46% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CURLF dives 46% YTD as domestic headwinds outweigh global growth; is it time to cash out or wait for a rebound?
CGCNegative Net Change TLRYPositive Net Change ACBPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Could the New Federal Bill Derail the U.S. Hemp Industry?
by Sundeep Ganoria
A proposed federal bill could upend the U.S. hemp market, threatening CBD and Delta-8 products now sold nationwide.
CGCNegative Net Change TLRYPositive Net Change CURLFPositive Net Change
marijuana medical pot-stocks
Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?
by Sundeep Ganoria
Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.
CGCNegative Net Change TLRYPositive Net Change ACBPositive Net Change VFFPositive Net Change
marijuana medical pot-stocks
Cannabis Operator VFF Sells Fresh Produce Unit: How to Play the Stock?
by Sundeep Ganoria
After dropping its produce business, Village Farms sharpens its cannabis focus - boosting exports, margins and market share.
CGCNegative Net Change TLRYPositive Net Change ACBPositive Net Change VFFPositive Net Change
marijuana medical pot-stocks
Aurora Cannabis Stock Rises 30% YTD: Time to Buy or Sell?
by Sundeep Ganoria
ACB's 30% YTD rally reflects Q3 strength, but flat EPS estimates and consumer weakness keep analysts cautious about long-term upside.
CGCNegative Net Change TLRYPositive Net Change ACBPositive Net Change
marijuana medical pot-stocks
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies
by Sundeep Ganoria
NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.
NVOPositive Net Change LLYNegative Net Change CRBPPositive Net Change SKYENegative Net Change
biotechs marijuana medical pharmaceuticals
Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?
by Sundeep Ganoria
While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.
SNYPositive Net Change NVOPositive Net Change CRBPPositive Net Change
marijuana medical
Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?
by Sundeep Ganoria
TLRY's pivot into beverages shows promise, but with falling cannabis sales and delisting risks, we recommend staying on the sidelines for now.
PMNegative Net Change JAZZNegative Net Change CRBPPositive Net Change TLRYPositive Net Change
marijuana medical pot-stocks
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZNegative Net Change PBYINegative Net Change NTLAPositive Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.
IIPRNegative Net Change LAMRNegative Net Change EPRPositive Net Change
cannabis finance marijuana reit